Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 11/20 | 0.57 |
| ▸ | SIK3 | Q9Y2K2 | 11/20 | 0.57 |
| ▸ | SIK1 | P57059 | 9/20 | 0.57 |
| ▸ | ABL1 | P00519 | 11/20 | 0.55 |
| ▸ | LCK | P06239 | 8/20 | 0.53 |
| ▸ | SRC | P12931 | 6/20 | 0.53 |
| ▸ | KIT | P10721 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 3/20 | 0.53 |
| ▸ | YES1 | P07947 | 3/20 | 0.53 |
| ▸ | LYN | P07948 | 3/20 | 0.53 |
| ▸ | HCK | P08631 | 3/20 | 0.53 |
| ▸ | BCR | P11274 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | FGR | P09769 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152015 | 1.00 | SIK2 (0.57) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL21875021 | 0.88 | SIK2 (0.71) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL23927248 | 0.86 | SIK2 (0.58) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL30152036 | 0.85 | SIK2 (0.57) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL23927264 | 0.85 | SIK2 (0.57) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL23927241 | 0.85 | SIK2 (0.81) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL30152001 | 0.85 | SIK2 (0.81) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL23927239 | 0.82 | SIK2 (0.76) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL23927235 | 0.82 | SIK2 (0.84) | SIK2SIK3SIK1ABL1LCK | |
| SCHEMBL30151989 | 0.82 | SIK2 (0.84) | SIK2SIK3SIK1ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-09-25 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023067021-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-04-27 | — | — | WO | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | SIK2 154/4885SIK3 180/4885SIK1 164/4885 |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | SIK3, SIK1, SIK2 | SIK2 3/4885SIK3 1/4885SIK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.